Wang, Jie

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Zhou, C., Wu, Y.-L., Chen, G., Feng, J., Liu, X.-Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., et al. (2011) · The Lancet Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 4,081

Assessment of blood tumor mutational burden as a potential biomarker for immunotherapy in patients with non-small cell lung cancer with use of a next-generation sequencing cancer gene panel

Wang, Z., Duan, J., Cai, S., Han, M., Dong, H., Zhao, J., Zhu, B., Wang, S., Zhuo, M., Sun, J., et al. (2019) · JAMA Oncology

Cancer Immunotherapy and BiomarkersCancer Genomics and Diagnostics

Cited by 471

Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial

Soria, J.-C., Wu, Y.-L., Nakagawa, K., Kim, S.-W., Yang, J.-J., Ahn, M.-J., Wang, J., Yang, J. C.-H., Lu, Y., Atagi, S., et al. (2015) · The Lancet Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 413

Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC

Gao, S., Li, N., Gao, S., Xue, Q., Ying, J., Wang, S., Tao, X., Zhao, J., Mao, Y., Wang, B., et al. (2020) · Journal of Thoracic Oncology

Cancer Immunotherapy and BiomarkersLung Cancer Diagnosis and Treatment

Cited by 401

Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial

Wang, J., Lu, S., Yu, X., Hu, Y., Sun, Y., Wang, Z., Zhao, J., Yu, Y., Hu, C., Yang, K., et al. (2021) · JAMA Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 396

Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial

Wu, Y.-L., Lu, S., Cheng, Y., Zhou, C., Wang, J., Mok, T., Zhang, L., Tu, H.-Y., Wu, L., Feng, J., et al. (2019) · Journal of Thoracic Oncology

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 357

Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial

Lu, S., Wang, J., Yu, Y., Yu, X., Hu, Y., Ai, X., Ma, Z., Li, X., Zhuang, W., Liu, Y., et al. (2021) · Journal of Thoracic Oncology

Lung Cancer Treatments and MutationsCancer Immunotherapy and Biomarkers

Cited by 284

Comutations in DNA Damage Response Pathways Serve as Potential Biomarkers for Immune Checkpoint Blockade

Wang, Z., Zhao, J., Wang, G., Zhang, F., Zhang, Z., Zhang, F., Zhang, Y., Dong, H., Zhao, X., Duan, J., et al. (2018) · Cancer Research

Cancer Immunotherapy and BiomarkersCancer Genomics and Diagnostics

Cited by 241

Camrelizumab Plus Apatinib in Extensive-Stage SCLC (PASSION): A Multicenter, Two-Stage, Phase 2 Trial

Fan, Y., Zhao, J., Wang, Q., Huang, D., Li, X., Chen, J., Fang, Y., Duan, J., Zhou, C., Hu, Y., et al. (2021) · Journal of Thoracic Oncology

Lung Cancer Research StudiesLung Cancer Treatments and Mutations

Cited by 135

ARTEMIS-001: Phase 1 study of HS-20093, a B7-H3–targeting antibody-drug conjugate, in patients with advanced solid tumor.

Wang, J., Duan, J., Xing, L., Sun, Y., Guo, W., Wang, H., Chen, J., Han, L., Liu, B., Wang, Q., et al. (2023) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersMonoclonal and Polyclonal Antibodies Research

Cited by 28